Showing 5181-5190 of 6036 results for "".
- FDA Approves Cystadrops for the Ocular Manifestations of Cystinosishttps://modernod.com/news/fda-approves-cystadrops-for-the-ocular-manifestations-of-cystinosis/2478201/Recordati Rare Diseases announced the FDA has approved Cystadrops (cysteamine ophthalmic solution 0.37%), a new, viscous eye drop solution that depletes corneal cystine crystal deposits in people living with cystinosis. Cystadrops demonstrated a significant reduction in cystine crystal deposits i
- SIFI Reports Positive Results From 044/si Phase 3 Clinical Trial of Netildex Gelhttps://modernod.com/news/sifi-reports-positive-results-from-044-si-phase-3-clinical-trial-of-netildex-gel/2478196/SIFI has announced the conclusion of a phase 3 clinical trial aimed at demonstrating the noninferiority of Netildex gel administered twice daily (BID) vs. Netildex solution administered four ti
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- Fewer Side Effects Helped Spur Pfizer, BioNTech to Advance BNT162b2 Over Earlier COVID-19 Vaccine Candidatehttps://modernod.com/news/fewer-side-effects-helped-spur-pfizer-biontech-to-advance-bnt162b2-over-earlier-covid-19-vaccine-candidate/2478189/Pfizer and BioNTech released more details about why they recently selected their experimental coronavirus vaccine BNT162b2 over another candidate to advance into late-stage testing. According to a paper available on the medRxiv preprint server presenting additional phase 1 data from an ongoing US
- Kubota Vision Receives Orphan Products Clinical Trial Grant for Stargardt Disease Treatment Candidatehttps://modernod.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/Kubota Vision announced that the FDA Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease. Orphan product clinical trial grants support well-controlled studies that will eithe
- Alcon Kicks Off Global Social Media Campaignhttps://modernod.com/news/alcon-kicks-off-global-social-media-campaign/2478183/Alcon kicked off a global social media campaign, “Reasons to Love Lenses,” during Contact Lens Health Week taking place August 17–21. The new campaign raises consumer awareness of the benefits of contact lens wear. The campaign also reiterates the value of prescribing contact lenses for eye care
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of 4D-125 for the Treatment of XLRPhttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-2-trial-of-4d-125-for-the-treatment-of-x-linked-retinitis-pigmentosa/2478179/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1/2 clinical trial of 4D-125 for X-linked retinitis pigmentosa (XLRP). 4D-125 is an AAV gene therapy with an optimized and proprietary vector designed to deliver a functional copy of the RPGR gene to pho
- Johnson & Johnson to Buy Momenta for $6.5 billionhttps://modernod.com/news/johnson-johnson-to-buy-momenta-for-6-5-billion/2478177/Johnson & Johnson entered into a definitive agreement to acquire Momenta Pharmaceuticals for $52.50 per share in cash, or approximately $6.5 billion, expanding its portfolio into autoantibody-driven autoimmune diseases. The transaction, which represents a premium of 70% to Momenta’s clo
- BVI Launches IPure Aspheric Monofocal IOL in the UShttps://modernod.com/news/bvi-launches-ipure-aspheric-monofocal-iol-in-the-us/2478172/BVI has entered the US IOL market with the launch of the IPure preloaded aspheric monofocal IOL. BVI says the IPure is the first and only preloaded aspheric monofocal IOL available in both a 1-piece and 3-piece design. IPure’s patented aspheric optic design provides high contract, hi
- EU Wraps Up Exploratory Talks With J&J to Secure Coronavirus Vaccinehttps://modernod.com/news/eu-wraps-up-exploratory-talks-with-jj-to-secure-coronavirus-vaccine/2478163/The European Commission said that it concluded exploratory talks with Johnson & Johnson to buy Ad26.COV2.S, the company’s vaccine candidate against COVID-19. Under the potential deal, once a vaccine has shown to be safe and effective against the novel coronavirus, the Commission s